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Background: Inflammatory neuropathies such as Guillain-Barré syndrome, chronic inflammatory demyelinating
polyradiculoneuropathy and paraproteinaemic demyelinating neuropathy are a heterogenous group of peripheral
nerve disorders that affect around one to two people per 100,000. Whilst treatments such as intravenous
immunoglobulin, plasma exchange and corticosteroids have generally positive results, long-term residual symptoms
and associated activity limitations are common.
There is currently no standardised care for patients with ongoing activity limitation and participation restriction as a
result of inflammatory neuropathy IN but data from observational studies and a randomised controlled trial suggest
that exercise either alone or as part of a multidisciplinary rehabilitation programme may be beneficial in improving
activity limitation. Tailoring the intervention for participants following physiotherapy assessment and incorporating
patient preference for type and location of exercise may be important.
Methods/Design: The current study is a pragmatic, prospective, parallel observer-blind, randomised controlled trial
to evaluate the efficacy and cost-effectiveness of a twelve week tailored home exercise programme versus advice
and usual care. Seventy adults with stable immune mediated inflammatory neuropathy IN will be recruited to the
study from two main sources: patients attending selected specialist peripheral nerve clinics in the South East and
West Midlands of England and people with who access the GAIN charity website or newsletter. Participants will be
randomised to receive either advice about exercise and usual care or a 12 week tailored home exercise programme.
The primary outcome of activity limitation and secondary outcomes of fatigue, quality of life, self-efficacy, illness beliefs,
mood and physical activity will be assessed via self-report questionnaire at baseline, 12 weeks and 12 months post
intervention. Cost effectiveness and cost utility will be assessed via interview at baseline and 12 months post
intervention.
Intention to treat analysis will be our primary model for efficacy analysis. Semi-structured interviews will be conducted
with a selected sample of participants in order to explore the acceptability of the intervention and factors affecting
adherence to the exercise programme.
Discussion: This is the first randomised controlled trial to compare the efficacy and cost-effectiveness of tailored home
exercise with advice about exercise and usual care for adults with inflammatory neuropathy.
Trial registration: Current Controlled Trials ISRCTN13311697
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Inflammatory immune mediated neuropathies (IN) are
a heterogenous group of peripheral nerve disorders that
affect around one to two people per 100,000 [1]. The
conditions share an immune-mediated pathophysio-
logical process but the clinical features may vary be-
tween conditions. Guillain-Barré syndrome (GBS) is an
acute inflammatory polyneuropathy, characterised by
rapidly progressive weakness, paralysis and sensory im-
pairment reaching nadir within four weeks of onset [2]
such that the majority of patients are unable to walk in-
dependently when maximum weakness is reached [3].
Prompt immunomodulatory treatment facilitates earlier
recovery that is generally good; with the majority of pa-
tients regaining mobility within six to twelve months
[4, 5] although residual problems are common and im-
provements may continue beyond this period [6].
Chronic inflammatory demyelinating polyradiculo-
neuropathy (CIDP) shares many characteristics with
GBS but presents a progressive or relapsing clinical
course [7]. There are a number of first-line, combination
and supportive treatments available for CIDP, [8] and
whilst many patients experience long-term improvement,
prognosis is variable and a significant proportion ex-
perience ongoing problems [4]. A related condition,
paraproteinaemic demyelinating neuropathy (PDN), is
characterised by an IgM monoclonal gammopathy with,
in about 50 % of cases, serum antibodies to myelin as-
sociated glycoprotein. PDN typically presents at an
older age than GBS and CIDP, with most cases present-
ing in the sixth decade or later and symptoms appear
similar to CIDP [4]. Despite differences in the initial
presentation and time course of GBS, CIDP and PDN,
the symptoms experienced by patients and the impact
of them on their daily lives are similar.
At least a third of people with IN experience long term
activity limitation. Residual symptoms may still be
present many years after recovery from GBS [9–12] and
CIDP [13]. One ten year follow-up study [14] showed
that 14 % of participants with GBS still had moderate to
severe disability and a further 50 % had more minor
symptoms, suggesting that residual disability may be
life-long. Fatigue is also a very common consequence
of IN with between 40 – 80 % of people reporting it
[15, 16]. It is often associated with reduced quality of
life [15] and greater activity limitation [14].
Persistent disability or fatigue experienced by people
with IN adversely affects their working and daily lives,
including family and social activities [9, 12, 13, 17–19].
Many people with IN need long-term informal care,
often supplemented by support from health and social
services [20]. People with IN are high users of services
[21] and the personal suffering, as well as health and
social care expenditure, increases as people live longer.Therefore, the potential for cost effective self-management
programmes aimed at improving disability, mood, societal
participation and quality of life should be evaluated.
There is currently no standardised care for patients
with ongoing activity limitation and participation re-
striction as a result of IN. A systematic review of the ef-
ficacy of exercise on disability in IN concluded that the
current evidence is of poor quality, although progres-
sive resisted strengthening exercise may moderately im-
prove muscle strength [22]. However, observational
studies show that supervised aerobic-cycling [23] or
unsupervised physiotherapist prescribed community
based aerobic and strengthening exercise [24] are asso-
ciated with an improvement in function, fatigue and
quality of life in people with IN. Further, one rando-
mised controlled trial showed that high intensity multi-
disciplinary rehabilitation that incorporated physiother-
apy for strengthening, endurance and gait training was
superior to low-intensity rehabilitation in improving
disability in people with GBS several years after recov-
ery [25]. Therefore exercise may be beneficial in im-
proving activity limitation after IN and tailoring the
intervention for participants following physiotherapy
assessment and incorporating patient preference for
type and location of aerobic and strengthening exercise
may be important [24].
A tailored approach to exercise prescription based on
our pilot study [24] has been developed for the current
study in light of social cognition theory [26]. The theory
suggests that behaviour is determined by the interaction
of current and previous behaviour, social, environmental
and cognitive factors such as social support, observa-
tional learning or modelling, outcome expectations, self-
efficacy, goal setting and self-regulation.
Thus, the current pragmatic randomised controlled
trial (RCT) includes a process evaluation that is under-
pinned by the transtheoretical model (TTM) for behav-
iour change [27]. The TTM has been shown to be useful
in understanding and predicting behaviour change
across a range of health behaviours including physical
activity [28, 29]. The model proposes a temporal dimen-
sion of stages of change (SoC) to describe the sequential
change in health related behaviours. The five stages of
change are: pre-contemplation, contemplation, prepar-
ation, action and maintenance [27, 30]. The model as-
sumes that the likelihood for behavioural change will be
dependent on the stage of change at which individuals
are currently at and that progress through the stages
may be complex. Factors such as self-efficacy and deci-
sional balance (the relative pros and cons of behaviour
change) have been consistently shown to increase in a
linear fashion alongside this progression through stages
[31], suggesting various potential factors to be targeted
for intervention.
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cise for the management of IN, the current RCT will
therefore assess the effectiveness, cost effectiveness and
cost utility of a tHEP versus advice about exercise and




Is a tailored home exercise programme more effective in
reducing disability (activity limitation) than advice about
exercise and usual care in people with stable inflamma-
tory immune-mediated neuropathy?
Primary hypothesis - a tailored home exercise
programme will be more beneficial than advice about
exercise and usual care in reducing activity limitation
for people with IN.
Secondary research questions
What is the cost-effectiveness and cost utility of a tHEP
compared with advice about exercise and usual care for
people with IN?
Are the health beliefs of people with IN associated
with their response to a tHEP versus advice about exer-
cise and usual care?
What are participants’ experiences of a tHEP and




The study is a pragmatic, prospective, parallel observer
blind, RCT to evaluate the efficacy and cost-effectiveness
of a twelve week tHEP versus advice and usual care.
Assessments will be taken at baseline, immediately fol-
lowing the intervention (twelve weeks) and at twelve
months. See Fig. 1. The single outcome assessor will re-
main blinded until the end of the twelve month follow-
up period but due to the nature of the intervention, the
participants and research physiotherapist will not be
blind to allocation.
Participants
Seventy adults with stable immune mediated IN will be
recruited to the study from two main sources: patients
attending selected specialist peripheral nerve clinics in
the South East and West Midlands of England and
people with IN who access the Guillain-Barré syndrome
and Associated Inflammatory Neuropathy (GAIN) charity
website or newsletter. Potential participants from clinics
will be approached by either their doctor or a member
of the research team (with the prior consent of the pa-
tient’s doctor) and provided with information about
the study. Alternatively, they will be sent an invitationletter and information sheet through the post. In both
cases, participants will be offered the opportunity to
discuss the project and ask questions. Signed consent
forms will be returned directly to the research team if
they decide to take part, either in person at the clinic,
or via the post once the participant has returned home.
Potential participants who access GAIN publications
will be approached by advertisements on their website and
newsletters. Potential participants will contact the re-
search team directly to receive information sheets and
to discuss the study prior to consenting to take part.
All potential participants will be screened for compliance
with the study inclusion criteria (below) and their diagno-
sis, IVIg therapy and fitness to participate will be con-
firmed with their GP or neurologist, with their consent.
Inclusion/exclusion criteria
Participants will be included if they fulfil the following
criteria:
1. They are adults with stable motor neuropathy, with
or without sensory neuropathy, as a result of GBS,
CIDP or PDN diagnosed using established criteria
[32, 33] (and where PDN is defined as the
combination of demyelinating neuropathy, serum
antibodies to myelin associated glycoprotein, and an
IgM monoclonal gammopathy with no evidence of
haematological malignancy)
2. They are able to walk 10 m, with or without
walking aids
3. They are at least one year since onset if they have GBS
4. They have had no change in self-reported disability,
immunotherapy or medication for neuropathic pain
in the previous six months (excepting medication
dose of azathioprine, which must not have changed
for twelve months). Patients receiving regular
intravenous immunoglobulin (IVIg) or plasma
exchange will be assessed at the same time points
after treatment to avoid fluctuations due to time
since last treatment. Minor alterations to IVIg
therapy in the lead-up to the project will be
allowed. A < =10 % change in the average weekly
dose will be allowed in the 3 months prior to entry
to the trial, and a change of < =20 % in the previous
6 months. If patients have received greater changes,
they will still be able to take part but must wait until
they meet these criteria
5. Participants should not have received physiotherapy
treatment in the six months prior to entering the
study. Once in the trial, patients may receive
additional physiotherapy for other unrelated
musculoskeletal problems if necessary but where
possible this should be postponed, at least until after
the twelve week intervention phase





Introductory letter and patient information sheet 
Baseline assessment – minimisation process for disability severity and IVIg use
(include planned secondary sensitivity analysis). 







tHEP – physical assessment, exercise 
prescription, advice about exercise and 
usual care meticulously documented
3 telephone 
contacts to facilitate 
adherence and 
progress exercise




Intention to treat (10 outcome - linear regression of change 
up to 12 months with adjustment for baseline, 20 outcomes 
with adjustment for severity). 
Per protocol analyses (if suitable adherence cut-off 
identified)
Exploratory secondary sub-group analysis for self-efficacy 
with threshold score identified
Qualitative 
analysis
Fig. 1 Study design flowchart. Flowchart depicting the process of recruitment, randomisation, data collection and data analysis throughout the trial
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English and are able to communicate responses to
questionnaires
Participants will be excluded from the study if they
fulfil any of the following criteria:
1. They score zero on the overall neuropathy
limitations scale (ONLS) [34], or 1 on the upper
limb scale alone (as this would reflect sensory
symptoms not affecting function)
2. They have any other unstable medical conditions
that a) affect activity limitation b) prevents themfrom exercising or c) would make it unsafe to
exercise
3. They are pregnant
4. They are adults who are unable to consent for
themselves
Sample size
The sample size is based on an 80 % power calculation
to detect a difference between mean change in the over-
all disability sum score (ODSS) [35] of 1 point using a 2
sided test at the 5 % significance level based on a SD of
1.27 from pilot study data [24]. Fifty-four people (27 per
group) will be needed; therefore 70 people will be
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months. The ODSS is a pre-cursor of the ONLS and
was used for sample size calculation as this was the rec-
ommended outcome measure of disability in IN at the
time of the pilot study.
Randomisation and allocation concealment
Participants will be allocated into either the treatment or
control group using randomisation with computerised
block minimisation to stratify for severity based on base-
line ONLS score (mild ≤ 3, moderate/severe ≥ 4) and re-
cruitment site to ensure even distribution between
groups. Participants will also be stratified by IVIg treat-
ment (yes/no) to minimise the likelihood that small
numbers of participants receiving this expensive therapy
may skew the cost-effectiveness analysis if not controlled
for across the groups. Randomisation will be conducted
by the King’s College London Clinical Trials Unit to en-
sure both the validity and balance of the randomisation
and support the successful blinding of the outcome as-
sessor for the intervention duration. Once allocation has
taken place, the outcome observer will receive a blinded
email confirming the participant number, and the re-
search physiotherapist will receive an un-blinded email
confirming participant number and allocation. In order
to maintain observer blindness throughout the study
period, participants will be requested not to discuss the
intervention with the outcome assessor.
Interventions
Control group
Participants allocated to the control group will receive
by post a letter advising them that they have been allo-
cated to the information and advice group and including
the UK Physical Activity Guidelines factsheet outlining
the benefits of regular exercise and the recommended
level of exercise for adults or older adults [36] and a
copy of the Physical Activity Readiness Questionnaire
(PAR-Q) [37]. This group will not receive any contact
with the study physiotherapist. They will receive any
other usual medical care which may include pharmaco-
logical, physical or other therapy interventions deemed
necessary by their doctor during the study period. Par-
ticipants will be requested to try and avoid having add-
itional physiotherapy for their IN during the study but
treatment not directly related to their IN will not be
restricted.
All referrals to other therapies and the specific inter-
ventions applied will be meticulously documented in
both groups using the Client Service Receipt Inventory
(CSRI) [38]. Data will include service utilisation in the
preceding month (home-help, personal and informal
care etc.) and less regularly used services in the preced-
ing twelve months (General Practitioner (GP) visits,hospital admission etc.). Informal care and financial
costs borne by carers will also be estimated and
recorded.
Intervention group
In addition to usual care (as characterised above) the
intervention group will be prescribed tHEP by the study
physiotherapist. Participants will undergo a clinical inter-
view and objective evaluation of their symptoms, activity
limitations and any underlying impairments likely to
affect their ability to exercise. In addition, in order to
foster uptake and adherence to exercise behaviour, the
therapist will ask participants to identify their prefer-
ences for exercise type and location and any factors that
they feel may affect their willingness or ability to carry
out a tHEP and how these may be overcome. This infor-
mation will be used to facilitate the development of indi-
vidualised exercise programmes tailored to take account
of participants SoC and personal beliefs and that include
physical activity and exercise goals identified by partici-
pants. Based on this assessment, the physiotherapist will
prescribe a tailored progressive programme of aerobic
and three strengthening exercises. Demonstration and
practice of each exercise will ensure participants are car-
rying them out effectively, safely and with the confidence
to continue exercising alone. Participants will be asked
to continue the programme by themselves at home for
twelve weeks. The therapist will advise participants on
how and when to progress their exercises and this will
be reinforced in follow-up telephone calls.
Aerobic exercise prescription will be informed by pre-
vious neurological exercise interventions [23, 24], evi-
dence based exercise guidelines [39, 40] and participant
preference. The dosage of exercise prescribed will be
based on the recommendations of the UK Activity
Guidelines [36]. Thus participants will be encouraged to
gradually build up to at least the minimum recom-
mended guideline amount of 150 min of moderate exer-
cise a week. Moderate intensity exercise such as brisk
walking or cycling should make adults feel as if they are
breathing harder and their heart is beating faster but
that they are still able to carry on a conversation. Partici-
pants will be taught how to use the Category Ratio 10
scale (CR-10) for rating of perceived exertion (RPE) [41]
to evaluate exercise intensity where moderate intensity is
graded at CR-10 grade 4.
Participants already meeting the guidelines at a mod-
erate level, or those participants who build up to this
level during the intervention period will be encouraged
to set goals to either increase the exercise duration or
to increase the intensity of exercise to a vigorous level
[42]. Vigorous intensity exercise such as running or
sporting activity, will make adults feel they are breath-
ing much harder, their hearts are beating rapidly and
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tion. This intensity of exercise is graded 7 on the CR-
10 of RPE [41].
Each participant will also be prescribed three strength-
ening exercises that target weak muscles, chosen from a
standardised menu of strengthening exercises compiled
by the study physiotherapist and informed by the literature
and evidence based exercise guidelines [24, 40, 43, 44].
Each exercise, and any modifications or progressions,
is facilitated by an exercise sheet supplied to the par-
ticipant, with written and pictorial instructions based
on those available on the peer reviewed website
www.physiotherapyexercises.com [45]. In order to stand-
ardise exercise intensity participants will be advised to
perform strengthening exercises at a RPE of 7–10 on
the CR-10 [41, 46] with the goal of achieving 3 sets of
8–10 repetitions of each exercise prior to progression.
Altering starting position may be used to eliminate or
increase the influence of gravity on muscle activity
and adding external resistance such as weighted bands
or elastic resistance bands, may be used to increase
the intensity of exercise as required. Examples of exer-
cises include: heel raises in standing, squats and knee
extension in sitting using weighted ankle bands.
Participants in the treatment group will receive a
minimum of three follow-up telephone calls from the
physiotherapist during the twelve week intervention
period. The physiotherapist will use the calls to encour-
age and monitor adherence, discuss any adaptations or
progressions to exercises and to review goals [47]. Par-
ticipants will be asked to complete a daily exercise
diary to monitor their adherence to the programme
and to record any adverse events or barriers to exercise
they encounter.
Adverse event reporting
Participants in both groups will be asked to contact ei-
ther the principal investigator or research physiother-
apist if they experience any adverse events during the
study/intervention period. All events will be recorded
and reviewed by the principal investigator and the par-
ticipant’s GP informed if appropriate. Serious adverse
events will be referred to the study sponsor and a
monitoring group will be convened in order to review
the event and ongoing trial safety. Adverse events will
be included as a secondary outcome of the study.
Outcome assessment
Primary outcome
Activity limitation will be assessed using the recently
validated Rasch based Overall Disability Scale (RODS)
[48]. This 24-item interval scale for activity limitation
has greater responsiveness than previous ordinal mea-
sures [49]. Scores for the RODS will be collected atbaseline, at the end of the twelve week intervention
period and at a twelve month follow up.
Secondary outcome measures
All of the following secondary outcome measures will be
assessed at baseline, twelve weeks and twelve months:
Activity limitation will also be assessed as a secondary
outcome using the Overall Neuropathy Limitations Scale
(ONLS) [34]. This is a 12 item ordinal scale of activity
limitation developed from the ODSS, which was used to
calculate sample size for the present study [35].
Fatigue will be assessed using the Rasch-modified
Fatigue Severity Scale (RFSS) [50]. This seven-item
scale is a Rasch-built modified version of the Fatigue
Severity Scale, and was developed specifically to address
fatigue in individuals with immune-mediated neuropathy.
The authors report good psychometric properties for
the scale.
Psychological wellbeing will be assessed using the Hospital
Anxiety and Depression Scale (HADS) [51]. The scale
consists of separate anxiety and depression subscales of
seven items each and has been found to correlate well
with other measures of depression and anxiety.
Functional health and well being will be assessed using
the Medical Outcomes Short Form 12 (SF-12). The
norms-based scoring system allows direct data compari-
sons to be made between the SF-12 and other generic
health surveys [52, 53].
Levels of physical activity will be assessed using the 7-
question International Physical Activity Questionnaire
(IPAQ-short). The questions ask participants to report
the frequency and duration of moderate activity, vigor-
ous activity and walking, and to rate the proportion of
time they spent sedentary in the previous week. The
scale has shown acceptable measurement properties,
similar to other self-report assessments [54].
Health beliefs will be assessed using the Brief Illness Per-
ceptions Questionnaire (Brief-IPQ) [55] developed from
the revised Illness Perceptions Questionnaire (IPQ-R)
[56]. Nine questions address participants beliefs with
regard to various features such as perceived severity of
consequences, perceived chronicity of an illness or con-
dition, and perceived control over the course or treat-
ment of a given condition. Participants respond on an
eleven point Likert scale (for example, 0 = no symptoms
at all, 10 = many severe symptoms).
Self-efficacy; an individuals confidence in their ability
to exercise, will be measured using the self-efficacy for
exercise (SEE) scale [57]. The scale examines 9 potential
barriers to exercise, such as feeling tired or depressed;
participants are asked to rate each item on an eleven
point Likert scale spanning the extent to which they
feel confident that they could exercise in the presence
of a particular barrier (0 = Not confident, 10 = Very
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(alpha 0.92) and good predictive validity for the scale [57].
Adherence to the tailored home exercise programme
in the study will be evaluated using a) the Exercise
Adherence Rating Scale (EARS) and b) self-report
diary entries.
a) The EARS has been developed based on the
Medication Adherence Rating Scale [58] and evaluates
barriers to adherence for prescribed exercise by asking
participants to rate, on a five-point Likert scale, the
extent to which they agree with sixteen statements
about their exercise adherence (for example, “I forget
to do my exercises”, “I’m not sure how to do my
exercises”). The EARS will only be completed by
participants randomised to the tHEP intervention.
b) Self-report exercise diaries record exercise type,
completion and factors affecting exercise. The
number of repetitions of strengthening exercise and
duration of aerobic exercise will be used to calculate
overall adherence as a proportion of the exercise
prescribed.
Cost-effectiveness and cost-utility analyses
In order to evaluate the cost-effectiveness and cost-utility
of the intervention in relation to advice and usual care,
participants in both groups will complete the Client
Services Receipt Inventory (CSRI) and the EQ-5D at
baseline and twelve month follow-up.
The CSRI is a scale developed for collecting data relating
to service use and has been used in a large number of
evaluations of health and social care interventions over
the past 30 years [38]. The questionnaire records the inter-
viewee’s use of health and social care services, accommo-
dation and living situation, income, employment and
benefits. Service use data are combined with appropriate
unit costs [59] to generate total care costs per patient. Lost
employment will be valued using average wage rates.
The EQ-5D [60] is a brief scale designed to measure
health related quality of life across five dimensions: mo-
bility, self-care, usual activities, pain/discomfort and anx-
iety/depression. For each domain participants are asked
to rate their current health using a five point scale to de-
scribe the extent to which they can perform activities
(“No problems” to “Unable to perform”). The scale also
includes a visual analogue scale on which participants
mark their current health status between 0 (worst health
they can imagine) and 100 (best health they can im-
agine). Quality Adjusted Life Years (QALYs) will be de-
rived from the EQ-5D scores for the cost-utility analysis.
Qualitative assessment of intervention acceptability
A purposive sub-sample of 8–10 participants from the
tHEP group and up to 5 from the usual care group willbe invited to attend a semi-structured interview follow-
ing completion of their twelve month follow-up to
evaluate participants’ experiences. Participants in the
tHEP group will be asked about their experience of the
tHEP and the factors that facilitate and impede adher-
ence to it. Participants in the usual care group will be
asked whether the advice they received prompted any
change in exercise or physical activity behaviour and
about their experience of exercise. The interviews will be
recorded, transcribed and undergo thematic analysis to
explore themes within the data [61].
Data analysis
Efficacy of intervention
For our primary outcome of activity limitation (RODS)
we will adjust for baseline score. For all other outcomes,
we will adjust for the severity stratification group using
ONLS baseline score, but not for the IVIg stratification
group as the likely low numbers will lead to an unstable
model.
Intention to treat analysis will be our primary model
for efficacy analysis. We will conduct a linear regression
of change from baseline to the twelve month follow up
and add in both intervention arm and baseline score. A
secondary analysis will examine changes between base-
line and 12 week follow up. Complete case analysis is
most often used but not ideal in this study as we have
small numbers. If we have some missing data at twelve
month follow up we can attempt to extrapolate based on
the data from participants with complete datasets if
there is less than 25 % missing data.
Per protocol analysis: If we can identify a suitable cut-
off from our measure of adherence we can also run a
per protocol analysis by removing those participants
from the dataset who did not complete enough of the
exercise intervention to be able to show an effect. However,
due to low numbers we do not wish to put the analysis at
risk by excluding too many.
We will also run an exploratory secondary subgroup
analysis of the self-efficacy data in order to see whether
self-efficacy influences the efficacy of the intervention.
A high/low score threshold will be identified for this
purpose.
Cost-effectiveness and cost-utility analyses
Costs generated from the CSRI will be added to costs of
the intervention. These will be derived from information
on staff time involved in delivering the intervention and
other non-staff costs. The endpoint for the economic
analysis will be twelve months when, if costs are lower
in the exercise group and outcome better, then the exer-
cise intervention will have been cost-effective. However,
if costs are higher and outcomes better then we will con-
struct cost-effectiveness acceptability curves to show the
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ferent values placed on a change in outcome. Cost-utility
analyses will be conducted in a similar way, but will use
QALYs as the outcome measure. Uncertainty around the
results will be explored using cost-effectiveness planes
and acceptability curves.
Participant experience and factors influencing adherence
Data from transcriptions of semi-structured interviews
will be analysed thematically to identify common themes
and connections between themes.
Discussion
This is the first randomised controlled trial to compare
the efficacy and cost-effectiveness of a tHEP with advice
about exercise and usual care in IN. A feasibility study
by this research group [24] provided evidence that tai-
lored home exercise is acceptable to individuals with IN
and that participation in a tHEP was associated with sig-
nificant improvements in activity limitation, fatigue,
quality of life and mood in an uncontrolled study.
There are two key strengths of the current RCT: firstly,
the integrity and quality of the intervention delivery is
enhanced by having one physiotherapist to conduct all
assessments and exercise prescription that includes the
use of behavioural change techniques to facilitate uptake
and adherence to the exercise, and second the qualitative
analysis of interviews with participants after completion
of the intervention, and the cost-effectiveness and cost-
utility analyses, will provide valuable information regard-
ing the acceptability and feasibility of the intervention as
a potential standard of care for individuals experiencing
activity limitation and participation restriction as a result
of stable IN.
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